MiniMed Group, Inc. (MMED)

NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-10-21

$17.80+1.77%

Close 2026-10-21 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 21, 2026

What could strengthen or challenge MiniMed Group, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+9.4%

+10% or more+5%0%−5%−10% or less

0.65 → 0.71 EPS · FY ending Apr 24, 2028 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 21, 2026 to Oct 21, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve positive free cash flow	A supporting condition in MiniMed Group, Inc.'s published investment case. The stated target is >=0.	Broken	free cash flow remains negative next fiscal year	Free cash flow: $-90M FY2026-Q1; GAAP. Published target: >=0. Target period is not explicitly aligned with this observation. Source published Sep 8, 2026-90,000,000 USD · calculatedSource reportLast status assessment Oct 20, 2026 Measurement source consolidated · GAAP FY2026-Q1 · Period ending Jul 31, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q1. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reach positive operating income	A primary condition in MiniMed Group, Inc.'s published investment case. The stated target is >=0.	Improving	operating income remains negative next fiscal year	Operating income: $5M FY2027-Q1; GAAP. Published target: >=0. Target period is not explicitly aligned with this observation. Source published Sep 8, 20265,000,000 USD · source valueSource reportLast status assessment Oct 20, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jul 31, 2026 Source: company_financial_results. Reference: 320e01e9-32f7-408b-8551-7ad8598f9cb3. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve at least 10% revenue growth	A primary condition in MiniMed Group, Inc.'s published investment case. The stated target is >=10% YoY.	Intact	falls below 10% revenue growth next fiscal year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 20, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-04-24 · fmp

FY2028 EPS$0.71

$0.69 → $0.71 · observed estimates

FY2028 revenue$3.72B

$3.70B → $3.72B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-08-27	$0.69	$3,699,351,046	5 / 10
2026-08-28	$0.69	$3,699,351,046	5 / 10
2026-08-29	$0.69	$3,699,351,046	5 / 10
2026-08-30	$0.69	$3,699,351,046	5 / 10
2026-08-31	$0.69	$3,699,351,046	5 / 10
2026-09-01	$0.69	$3,699,351,046	5 / 10
2026-09-02	$0.66	$3,706,449,853	5 / 10
2026-09-03	$0.66	$3,712,329,728	6 / 10
2026-09-04	$0.66	$3,712,329,728	6 / 10
2026-09-05	$0.66	$3,712,329,728	6 / 10
2026-09-06	$0.66	$3,712,329,728	6 / 10
2026-09-07	$0.66	$3,712,329,728	6 / 10
2026-09-08	$0.66	$3,712,329,728	6 / 10
2026-09-09	$0.66	$3,712,329,728	6 / 10
2026-09-10	$0.66	$3,712,496,395	6 / 10
2026-09-11	$0.66	$3,712,496,395	6 / 10
2026-09-12	$0.66	$3,712,496,395	6 / 10
2026-09-13	$0.66	$3,712,496,395	6 / 10
2026-09-14	$0.66	$3,712,496,395	6 / 10
2026-09-15	$0.66	$3,712,496,395	6 / 10
2026-09-16	$0.65	$3,712,239,150	5 / 9
2026-09-17	$0.65	$3,712,239,150	5 / 9
2026-09-18	$0.65	$3,712,239,150	5 / 9
2026-09-19	$0.65	$3,712,239,150	5 / 9
2026-09-20	$0.65	$3,712,239,150	5 / 9
2026-09-21	$0.65	$3,712,239,150	5 / 9
2026-09-22	$0.65	$3,710,539,184	5 / 9
2026-09-23	$0.65	$3,710,539,184	5 / 9
2026-09-24	$0.65	$3,710,539,184	5 / 9
2026-09-25	$0.65	$3,714,494,252	5 / 9
2026-09-26	$0.65	$3,714,519,252	5 / 10
2026-09-27	$0.65	$3,714,519,252	5 / 10
2026-09-28	$0.65	$3,714,519,252	5 / 10
2026-09-29	$0.65	$3,714,519,252	5 / 10
2026-09-30	$0.65	$3,714,519,252	5 / 10
2026-10-01	$0.65	$3,714,519,252	5 / 10
2026-10-02	$0.65	$3,714,352,585	5 / 10
2026-10-03	$0.65	$3,714,352,585	5 / 10
2026-10-04	$0.65	$3,714,352,585	5 / 10
2026-10-05	$0.65	$3,714,352,585	5 / 10
2026-10-06	$0.65	$3,714,352,585	5 / 10
2026-10-07	$0.68	$3,714,352,585	5 / 10
2026-10-08	$0.68	$3,714,352,585	5 / 10
2026-10-09	$0.68	$3,714,352,585	5 / 10
2026-10-10	$0.68	$3,714,352,585	5 / 10
2026-10-11	$0.68	$3,714,352,585	5 / 10
2026-10-12	$0.68	$3,714,352,585	5 / 10
2026-10-13	$0.70	$3,713,272,386	5 / 11
2026-10-14	$0.71	$3,720,877,931	5 / 11
2026-10-15	$0.71	$3,720,713,646	6 / 11
2026-10-16	$0.71	$3,720,713,646	6 / 11
2026-10-17	$0.71	$3,720,713,646	6 / 11
2026-10-18	$0.71	$3,720,354,475	7 / 12
2026-10-19	$0.71	$3,720,354,475	7 / 12
2026-10-20	$0.71	$3,720,354,475	7 / 12
2026-10-21	$0.71	$3,720,354,475	7 / 12

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	12	1	0
2026-06-01	11	1	0
2026-07-01	11	1	0
2026-08-01	11	1	1
2026-09-01	11	1	2
2026-10-01	13	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 3 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 22–Oct 21 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Redburn PartnersOct 13

$30.00New observation · no comparable prior

JefferiesOct 12

$22.00New observation · no comparable prior

Mizuho SecuritiesOct 8 · prior Sep 2

$26.00 → $28.00+7.7%

BarclaysOct 6

$22.00New observation · no comparable prior

Truist FinancialSep 24

$29.00New observation · no comparable prior

$0$16.50$33.00

1 raises · 0 cuts · 0 unchanged · 4 without a comparable prior

How this is measured

Sep 22, 2026–Oct 21, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve positive free cash flowPublished status: Broken
Reach positive operating incomeOperating income: $5M
Achieve at least 10% revenue growthDirect metric needs a verified mapping

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-41.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

MiniMed Group, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 17, 2026

What kind of bet this is

This is a growth-focused healthcare business with execution and sector risks, rather than a proven durable compounder. The long-term thesis is intact, though evidence is limited and management execution is assessed as neutral overall.

What's priced into MiniMed Group, Inc.

The valuation evidence is mixed: one measure describes MMED as cheap versus peers, while another shows a 48% premium to peers. The model has low confidence, and the expectations gap is negative, so the evidence does not give a clear picture of what the market assumes.

What the fundamentals likely do

In the latest reported quarter, revenue rose from $723 million to $843 million year over year, with growth in both U.S. and international sales. New-pump sales also grew, and management reported pipeline milestones, although progress on innovation was assessed as mixed. Near-term earnings remain uncertain given a record of misses and erratic surprises, despite a recent reported earnings beat.

What MiniMed Group, Inc. hinges on

Over the next few quarters, continued sales growth and delivery on product launches and pipeline milestones would support the multi-year view. A weakening jobs trend could weigh on cyclical healthcare names, while continued earnings strength from sector bellwether FONR could sustain sector momentum; misses or lower guidance from FONR could weaken that support.